FRM
AKBA icon

Fox Run Management’s Akebia Therapeutics AKBA Stock Holding History

Fox Run Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,174
Closed -$116K – 644
2018
Q1 		$116K Sell
12,174
-15,376
-56% -$215K 0.03% 673
2017
Q4 		$410K Buy
+27,550
New +$457K 0.12% 353
2017
Q3 		– Sell
-18,800
Closed -$270K – 648
2017
Q2 		$270K Buy
+18,800
New +$238K 0.09% 448

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fox Run Management's AKBA Position: Q2 2018 in Review

Fox Run Management sold out of Akebia Therapeutics (AKBA) in Q2 2018, closing a stake of 12,174 shares — an estimated $116K sold.

Fox Run Management first reported a position in AKBA in Q2 2017 and held it in 3 quarters. The position peaked at $410K in Q4 2017. 145 funds tracked by Wall St. Rank hold AKBA as of Q2 2018.

  • Fox Run Management reported no remaining Akebia Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Fox Run Management sold 12,174 Akebia Therapeutics shares in Q2 2018, an estimated $116K.
  • Fox Run Management first reported a position in Akebia Therapeutics in Q2 2017 and held it in 3 quarters.
  • Fox Run Management's Akebia Therapeutics position peaked at $410K in Q4 2017.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2018.

Based on Fox Run Management's 13F filing for Q2 2018, filed 17 Jul 2018.